And Rasopathies-Associated SHP2 and BRAF Mutations
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent -
The Role of HIF-1Α in Sarcoma Metastasis and Response to Radiation Therapy
The Role of HIF-1α in Sarcoma Metastasis and Response to Radiation Therapy by Minsi Zhang Department of Pharmacology and Cancer Biology Duke University Date:_______________________ Approved: ___________________________ David Kirsch, Supervisor ___________________________ Mark Dewhirst ___________________________ Christopher Kontos ___________________________ Kenneth Poss ___________________________ Jeffrey Rathmell Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology and Cancer Biology in the Graduate School of Duke University 2015 ABSTRACT The Role of HIF-1α in Sarcoma Metastasis and Response to Radiation Therapy by Minsi Zhang Department of Pharmacology and Cancer Biology Duke University Date:_______________________ Approved: ___________________________ David Kirsch, Supervisor ___________________________ Mark Dewhirst ___________________________ Christopher Kontos ___________________________ Kenneth Poss ___________________________ Jeffrey Rathmell An abstract of a dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology and Cancer Biology in the Graduate School of Duke University 2015 Copyright by Minsi Zhang 2015 Abstract The degree of intratumoral hypoxia is clinically correlated to poor response to therapy and increased incidence of distal spread in various cancer subtypes. Specifically, the transcription factor Hypoxia Inducible Factor-1α (HIF- 1α), which is accumulated in cells in response to a hypoxic microenvironment, is implicated in poor disease outcome associated with intratumoral hypoxia. Using novel genetically engineered mouse models of primary soft tissue sarcoma, I show that in vivo genetic deletion of HIF-1α specifically in tumor cells 1) decreases the incidence of lung metastases by limiting sarcoma collagen deposition, and 2) improves sarcoma response to radiation therapy by limiting the inflammatory response and metabolic adaptations. -
Profiling Data
Compound Name DiscoveRx Gene Symbol Entrez Gene Percent Compound Symbol Control Concentration (nM) JNK-IN-8 AAK1 AAK1 69 1000 JNK-IN-8 ABL1(E255K)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317I)-nonphosphorylated ABL1 87 1000 JNK-IN-8 ABL1(F317I)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317L)-nonphosphorylated ABL1 65 1000 JNK-IN-8 ABL1(F317L)-phosphorylated ABL1 61 1000 JNK-IN-8 ABL1(H396P)-nonphosphorylated ABL1 42 1000 JNK-IN-8 ABL1(H396P)-phosphorylated ABL1 60 1000 JNK-IN-8 ABL1(M351T)-phosphorylated ABL1 81 1000 JNK-IN-8 ABL1(Q252H)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(Q252H)-phosphorylated ABL1 56 1000 JNK-IN-8 ABL1(T315I)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(T315I)-phosphorylated ABL1 92 1000 JNK-IN-8 ABL1(Y253F)-phosphorylated ABL1 71 1000 JNK-IN-8 ABL1-nonphosphorylated ABL1 97 1000 JNK-IN-8 ABL1-phosphorylated ABL1 100 1000 JNK-IN-8 ABL2 ABL2 97 1000 JNK-IN-8 ACVR1 ACVR1 100 1000 JNK-IN-8 ACVR1B ACVR1B 88 1000 JNK-IN-8 ACVR2A ACVR2A 100 1000 JNK-IN-8 ACVR2B ACVR2B 100 1000 JNK-IN-8 ACVRL1 ACVRL1 96 1000 JNK-IN-8 ADCK3 CABC1 100 1000 JNK-IN-8 ADCK4 ADCK4 93 1000 JNK-IN-8 AKT1 AKT1 100 1000 JNK-IN-8 AKT2 AKT2 100 1000 JNK-IN-8 AKT3 AKT3 100 1000 JNK-IN-8 ALK ALK 85 1000 JNK-IN-8 AMPK-alpha1 PRKAA1 100 1000 JNK-IN-8 AMPK-alpha2 PRKAA2 84 1000 JNK-IN-8 ANKK1 ANKK1 75 1000 JNK-IN-8 ARK5 NUAK1 100 1000 JNK-IN-8 ASK1 MAP3K5 100 1000 JNK-IN-8 ASK2 MAP3K6 93 1000 JNK-IN-8 AURKA AURKA 100 1000 JNK-IN-8 AURKA AURKA 84 1000 JNK-IN-8 AURKB AURKB 83 1000 JNK-IN-8 AURKB AURKB 96 1000 JNK-IN-8 AURKC AURKC 95 1000 JNK-IN-8 -
Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1. -
Transcriptomic Uniqueness and Commonality of the Ion Channels and Transporters in the Four Heart Chambers Sanda Iacobas1, Bogdan Amuzescu2 & Dumitru A
www.nature.com/scientificreports OPEN Transcriptomic uniqueness and commonality of the ion channels and transporters in the four heart chambers Sanda Iacobas1, Bogdan Amuzescu2 & Dumitru A. Iacobas3,4* Myocardium transcriptomes of left and right atria and ventricles from four adult male C57Bl/6j mice were profled with Agilent microarrays to identify the diferences responsible for the distinct functional roles of the four heart chambers. Female mice were not investigated owing to their transcriptome dependence on the estrous cycle phase. Out of the quantifed 16,886 unigenes, 15.76% on the left side and 16.5% on the right side exhibited diferential expression between the atrium and the ventricle, while 5.8% of genes were diferently expressed between the two atria and only 1.2% between the two ventricles. The study revealed also chamber diferences in gene expression control and coordination. We analyzed ion channels and transporters, and genes within the cardiac muscle contraction, oxidative phosphorylation, glycolysis/gluconeogenesis, calcium and adrenergic signaling pathways. Interestingly, while expression of Ank2 oscillates in phase with all 27 quantifed binding partners in the left ventricle, the percentage of in-phase oscillating partners of Ank2 is 15% and 37% in the left and right atria and 74% in the right ventricle. The analysis indicated high interventricular synchrony of the ion channels expressions and the substantially lower synchrony between the two atria and between the atrium and the ventricle from the same side. Starting with crocodilians, the heart pumps the blood through the pulmonary circulation and the systemic cir- culation by the coordinated rhythmic contractions of its upper lef and right atria (LA, RA) and lower lef and right ventricles (LV, RV). -
MYLK4, Active Recombinant Full-Length Human Protein Expressed in Sf9 Cells
Catalog # Aliquot Size M74-10G-05 5 µg M74-10G-10 10 µg MYLK4, Active Recombinant full-length human protein expressed in Sf9 cells Catalog # M74-10G Lot # Z1 313 -3 Product Description Specific Activity Recombinant full-length human MYLK4 was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. 16,000 The MYLK4 gene accession number is BC132833 . 12,000 Gene Aliases 8,000 SGK085 4,000 (cpm) Activity Formulation 0 0 50 100 150 200 Recombinant protein stored in 50mM Tris-HCl, pH 7.5, Protein (ng) 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM The specific activity of MYLK4 was determined to be 5 nmol DTT, 0.1mM PMSF, 25% glycerol. /min/mg as per activity assay protocol. Storage and Stability Purity Store product at –70 oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. The purity of MYLK4 was determined to be >95% by Scientific Background densitometry. Approx. MW 70kDa . MYLK4 or myosin light chain kinase family, member 4 is Serine/Threonine protein kinases in which MYLK4 is one of four myosin light chain kinases in a comprehensive analysis of protein kinases encoded by the human genome. References MYLK4, Active Recombinant full-length human protein expressed in Sf9 cells 1. Manning G. et.al : The protein kinase ment of the human genome. Science. 2002 Dec 6;298(5600):1912-34. Catalog # M74-10G Specific Activity 5 nmol/min/mg Lot # Z1313-3 Purity >95% Concentration 0.1 µg/ µl Stability 1yr at –70 oC from date of shipment Storage & Shipping Store product at –70 oC. -
PRODUCTS and SERVICES Target List
PRODUCTS AND SERVICES Target list Kinase Products P.1-11 Kinase Products Biochemical Assays P.12 "QuickScout Screening Assist™ Kits" Kinase Protein Assay Kits P.13 "QuickScout Custom Profiling & Panel Profiling Series" Targets P.14 "QuickScout Custom Profiling Series" Preincubation Targets Cell-Based Assays P.15 NanoBRET™ TE Intracellular Kinase Cell-Based Assay Service Targets P.16 Tyrosine Kinase Ba/F3 Cell-Based Assay Service Targets P.17 Kinase HEK293 Cell-Based Assay Service ~ClariCELL™ ~ Targets P.18 Detection of Protein-Protein Interactions ~ProbeX™~ Stable Cell Lines Crystallization Services P.19 FastLane™ Structures ~Premium~ P.20-21 FastLane™ Structures ~Standard~ Kinase Products For details of products, please see "PRODUCTS AND SERVICES" on page 1~3. Tyrosine Kinases Note: Please contact us for availability or further information. Information may be changed without notice. Expression Protein Kinase Tag Carna Product Name Catalog No. Construct Sequence Accession Number Tag Location System HIS ABL(ABL1) 08-001 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) BTN BTN-ABL(ABL1) 08-401-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ABL(ABL1) [E255K] HIS ABL(ABL1)[E255K] 08-094 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) HIS ABL(ABL1)[T315I] 08-093 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) [T315I] BTN BTN-ABL(ABL1)[T315I] 08-493-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ACK(TNK2) GST ACK(TNK2) 08-196 Catalytic domain -
Skeletal Muscle Gene Expression in Long-Term Endurance and Resistance Trained Elderly
International Journal of Molecular Sciences Article Skeletal Muscle Gene Expression in Long-Term Endurance and Resistance Trained Elderly 1,2, 3, 1,2, Alessandra Bolotta y, Giuseppe Filardo y, Provvidenza Maria Abruzzo *, Annalisa Astolfi 4,5 , Paola De Sanctis 1, Alessandro Di Martino 6, Christian Hofer 7, Valentina Indio 4 , Helmut Kern 7, Stefan Löfler 7 , Maurilio Marcacci 8, Sandra Zampieri 9,10, 1,2, 1, Marina Marini z and Cinzia Zucchini z 1 Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna School of Medicine, 40138 Bologna, Italy; [email protected] (A.B.); [email protected] (P.D.S.); [email protected] (M.M.); [email protected] (C.Z.) 2 IRCCS Fondazione Don Carlo Gnocchi, 20148 Milan, Italy 3 Applied and Translational Research Center, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; g.fi[email protected] 4 Giorgio Prodi Interdepartimental Center for Cancer Research, S.Orsola-Malpighi Hospital, 40138 Bologna, Italy; annalisa.astolfi@unibo.it (A.A.); [email protected] (V.I.) 5 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy 6 Second Orthopaedic and Traumatologic Clinic, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy; [email protected] 7 Ludwig Boltzmann Institute for Rehabilitation Research, 1160 Wien, Austria; [email protected] (C.H.); [email protected] (H.K.); stefan.loefl[email protected] (S.L.) 8 Department of Biomedical Sciences, Knee Joint Reconstruction Center, 3rd Orthopaedic Division, Humanitas Clinical Institute, Humanitas University, 20089 Milan, Italy; [email protected] 9 Department of Surgery, Oncology and Gastroenterology, University of Padua, 35122 Padua, Italy; [email protected] 10 Department of Biomedical Sciences, University of Padua, 35131 Padua, Italy * Correspondence: [email protected]; Tel.: +39-051-2094122 These authors contributed equally to this work. -
Unit Name Gene Name Forward Sequence Reverse Sequence
SupplTable2.xls Unit name Gene name Forward sequence Reverse sequence AKAP13_0 AKAP13 CAGTGATGTGTCTCTCTCC GTTCTCTCTGGTCTGACTC APAF1_0 APAF1 GGACCCTCAAGAGGATATG GAAAGTACTGTACCCTGGTG ARID4B_0 ARID4B GAGGAGTACTGTAGATCAGC TGGCATCAGTGAGATCCAG ASC_0 ASC CTTCTACCTGGAGACCTAC GTAGGACTGGGACTCCCTTA AXIN1_0 AXIN1 GAGGCTACTCAGAGAGTGTT CAGAAGTAGTACGCCACAAC AXL_0 AXL CCCCTGAGAACATTAGTGCT AGAGCCAAGATGAGGACACA AXUD1_0 AXUD1 GTCCGGCACCACCATGACT GATGTGAAGCTACAGCCAG BAX_0 BAX GAGCAGATCATGAAGACAGG GTCCCAAAGTAGGAGAGGA BCL2L11_0 BCL2L11 TACCTCCCTACAGACAGAG CCTCCTTGCATAGTAAGCGT BCL2L12_0 BCL2L12 TCCTAGCTGCCTTCCTTAG GTATGGCTTCCTTCTCTGTC BCL2L1_0 BCL2L1 ATGGCAGCAGTAAAGCAAGCG TCATTTCCGACTGAAGAGTGA BCLAF1_0 BCLAF1 GTACCCTGAGGAAGCATAC AGTACCACGACCTCTTCCT BIRC5_0 BIRC5 CCACCGCATCTCTACATTCA CTGGTGCCACTTTCAAGACA BNIP1_0 BNIP1 CCGGATCTGTAACCAAGAG CTTAAGAGATCTCCTCCCTG BNIP1_1 BNIP1 CAACTCTCCAACTACACCTG CTCTCAGTGATGGTACTGG BRAF_0 BRAF GAGAGGTCTAATCCCAGAGT CACGTTAGTTAGTGAGCCAG BRCA1_0 BRCA1 CTAACAGCTACCCTTCCATC ACCACATCTCCTCTGACTTC BRCA1_1 BRCA1 GTCTCAGTGTCCAACTCTCT GTCACTCTGAGAGGATAGC C11orf17_0 C11orf17 CTCTAGAAGTGCTGGAGAG GACCATTCCCTATGTCCAAG C11orf17_1 C11orf17 GTTATCACAGAGGCGAGTC CAACTGCTACCACATGAGTC CARD10_0 CARD10 GAGTTCTACTACCCCGAAC CTCAGAGACAAGGTCCACAT CARD10_1 CARD10 GTGGACCTTGTCTCTGAGC GTACAGGTCACAGTCCTTC CASP10_0 CASP10 AGACTCGCTTCCCAAAACTG ATCTGCTTCGATGGATACGG CASP1_0 CASP1 AGGTCCTGAAGGAGAAGAG CCTCCACATCACAGGAACA CASP4_0 CASP4 GGGTCATGGCAGACTCTAT CTATAGTCCAGACCCTCAAG CASP6_0 CASP6 ATGAGCTCGGCCTCGGGG GGCTGCATCCACCTCAGTTA CASP7_0 CASP7 GACCGAGTGCCTACATATC GCTCCTCCACGAGTAATAG -
Deciphering Additional Mechanisms of Mtorc1 Signaling in Skeletal
Deciphering additional mechanisms of mTORC1 signaling in skeletal muscle Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Kathrin Chojnowska aus Deutschland Basel, 2019 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Markus A. Rüegg Prof. Dr. Christoph Handschin Basel, den 19.02.2019 Prof. Dr. Martin Spiess Dekan der Philosophisch-Naturwissenschaftlichen Fakultät Table of Content 1 Acknowledgements ........................................................................................................... 7 2 List of Abbreviations .......................................................................................................... 9 3 Aim of the Study .............................................................................................................. 13 4 Outline of the Thesis ....................................................................................................... 15 5 Introduction ...................................................................................................................... 17 5.1 Skeletal muscle in health and disease- a metabolic organ ...................................... 17 5.2 mTORC1 and its role in skeletal muscle .................................................................. 19 6 Chapter 1: Sustained activation of mTORC1 in skeletal -
Investigating the Effect of Chronic Activation of AMP-Activated Protein
Investigating the effect of chronic activation of AMP-activated protein kinase in vivo Alice Pollard CASE Studentship Award A thesis submitted to Imperial College London for the degree of Doctor of Philosophy September 2017 Cellular Stress Group Medical Research Council London Institute of Medical Sciences Imperial College London 1 Declaration I declare that the work presented in this thesis is my own, and that where information has been derived from the published or unpublished work of others it has been acknowledged in the text and in the list of references. This work has not been submitted to any other university or institute of tertiary education in any form. Alice Pollard The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives license. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, researchers must make clear to others the license terms of this work. 2 Abstract The prevalence of obesity and associated diseases has increased significantly in the last decade, and is now a major public health concern. It is a significant risk factor for many diseases, including cardiovascular disease (CVD) and type 2 diabetes. Characterised by excess lipid accumulation in the white adipose tissue, which drives many associated pathologies, obesity is caused by chronic, whole-organism energy imbalance; when caloric intake exceeds energy expenditure. Whilst lifestyle changes remain the most effective treatment for obesity and the associated metabolic syndrome, incidence continues to rise, particularly amongst children, placing significant strain on healthcare systems, as well as financial burden. -
Supporting Information
Supporting Information Faltermeier et al. 10.1073/pnas.1521674112 A. FU-R1-R2-V5-SV40-BlasƟ-CGW UbiquiƟn-C CMV 5’ LTR R1 Kinase R2 V5 SV40 BlastiR 3’ LTR promoter promoter GFP B. Kinase (kDa) 210 CMV GFP WPR 105 promot E er 78 49 38 28 V5 293t cells Fig. S1. Lentivirus-mediated overexpression of V5-tagged kinases. (A) Full-length kinases were cloned into the FU-R1-R2-V5-SV40-Blasti-CGW lentiviral vector shown. R1 and R2 represent recombination sites required for recombination-based Gateway cloning. LTR, Long-terminal repeat. (B) Western blot showing expression of selected kinases in 293t cells detected by a V5 antibody. The molecular mass of each kinase is indicated in parentheses. A. vector SrcY529F 3 Cap8 cells 2 weeks 2 x107 Tail vein Y529F Src injecƟon SCID 1 Luciferase reporter BLI Radiance (p/sec/cm3/sr) B. Lungs from mice injected with Cap8-SrcY529F cells Mouse 1 Mouse 2 Fig. S2. SrcY529F promotes lung colonization when overexpressed in murine prostate cells. (A) Experimental design to demonstrate that expression of mu- tationally activated kinase SrcY529F in Cap8 cells promotes lung colonization. (B) Bright-field images of lungs removed from mice 3 wk after being injected with Cap8-SrcY529F cells. (Scale bars, 5 mm.) Faltermeier et al. www.pnas.org/cgi/content/short/1521674112 1of5 A. Lungs-NTRK2 210 105 NTRK2 78 49 38 V5 293t cells Metastases Ɵssue Lungs-EGFR 210 EGFR 105 78 49 38 V5 293t cells Metastases Ɵssues Lungs-Her2 210 105 HER2 78 49 38 V5 293t cells Metastases Ɵssues B.